Canada reported on April 13 its first case of a rare but potentially fatal blood clot after an individual received the AstraZeneca COVID-19 vaccine.
In separate statements, Quebec’s Health Ministry and the Public Health Agency of Canada confirmed the blood clot case from a woman who received the vaccine made at the Serum Institute of India.
“The person was taken care of by the health and social services network and received the care appropriate to their condition,” Quebec’s Health Ministry said in a statement, adding that she is recovering from home.
Officials did not specify the age of the woman.
Quebec Health Minister Christian Dubé said at a press conference that the province is taking a “hypervigilant” approach to monitor any adverse reactions linked to the vaccine.
Canada’s Chief Public Health Officer Dr. Theresa Tam similarly said officials will monitor any serious adverse reactions related to the vaccine.
Dubé also said that the blood clot case was a possibility that health officials “expected.”
“We have been very transparent that there could be one case per 100,000,” Dubé said.
Last March, the National Advisory Committee on Immunization recommended to suspend the use of the vaccine for those under the age of 55 because most blood clot cases involved younger vaccine recipients.
Health Canada has added a warning about the potential risk of blood clots linked to the vaccine, but also said that based on the present information it has, the benefits continue to outweigh the risks.
Health experts and drug regulators also said that the risk of blood clots from the vaccines is lower than the virus itself.
According to Quebec’s health ministry, it has administered 185,000 doses of the vaccine so far.
As of April 3, Canada has administered 700,00 doses of the vaccine.
© Fourth Estate
® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.